Live Updates: U.S. recommends “pause” for Johnson & Johnson COVID vaccine to review blood clot cases – CBS News

The Centers for Disease Control suggested in an alert Tuesday that the Johnson & & Johnson vaccine could resume as soon as Wednesday. The alert came after a disorderly day when the Food and Drug Administration advised there be a “time out” for the vaccine, leading virtually every state to stop use of the single-dose shot.
The CDCs Advisory Committee on Immunization Practices will convene Wednesday for an emergency situation session, with a vote scheduled on “upgraded recommendations for usage” before the group adjourns at 4:30 p.m. ET.
Dr. Anthony Fauci, President Bidens primary medical consultant, told “CBS Evening News” anchor Norah ODonnell on Tuesday night that it appeared that the negative impact took place within 6 to 13 days, and “so if youve had it a month or 2 ago, I believe you actually dont need to fret about anything.”
Fauci emphasized that the possibility of these unfavorable negative effects is “less than 1 in a million,” but he said to be alert to the signs such as severe headache, some problem in movement– such as in a neurological kind of a scenario– or some chest pain and problem breathing.
Since Monday, more than 6.8 million doses of the Johnson & & Johnson vaccine had been administered throughout the U.S., a small part of the general 190 million COVID vaccine shots provided nationwide– most of them from Pfizer and Moderna.
The White House stated Tuesday that the pause “will not have a considerable impact” on the across the country vaccine strategy. President Biden assured Americans that he had actually made certain the U.S. has enough vaccine doses for all American adults from Pfizer and Moderna alone..
The handful of cases the FDA and CDC are investigating took place in women and involved a blood embolism called cerebral venous sinus apoplexy, which was seen alongside low levels of blood platelets, according to their statement. Symptoms were seen six to 13 days after vaccination in the ladies, who were between the ages of 18 and 48.
” Treatment of this particular kind of embolism is different from the treatment that may normally be administered. Typically, an anticoagulant drug called heparin is used to deal with blood embolisms. In this setting, administration of heparin may threaten, and alternative treatments need to be offered,” they said.
The firms said the “adverse occasions” appear to be exceptionally uncommon, but that the time out is essential so that health care suppliers can be made conscious of the responses and appropriately recognize and handle the cases, given the distinct treatment needed.
Ed OKeefe added to this report.

Leave a Reply

Your email address will not be published. Required fields are marked *